Essential health services

Interim recommendations for use of the Moderna mRNA-1273 vaccine against COVID-19: interim guidance, first issued 25 January 2021, updated 15 June 2021

Interim recommendations for the use of the Janssen Ad26.COV2.S (‎COVID-19)‎ vaccine: interim guidance, first issued 17 March 2021, updated 15 June 2021

Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac: interim guidance, 24 May 2021

Interim recommendations for use of the inactivated COVID-19 vaccine BIBP developed by China National Biotec Group (‎CNBG)‎, Sinopharm: interim guidance, 7 May 2021

Fact sheet for health workers: Moderna COVID-19 (‎mRNA-1273)‎ vaccine (2021)

Estimating COVID-19 vaccine effectiveness against severe acute respiratory infections (‎SARI)‎ hospitalisations associated with laboratory-confirmed SARS-CoV-2: an evaluation using the test-negative design: guidance document (2021)

Interim recommendations for use of the Moderna mRNA-1273 vaccine against COVID-19: interim guidance, 25 January 2021

Interim recommendations for use of the AZD1222 (‎ChAdOx1-S [‎recombinant]‎)‎ vaccine against COVID19 developed by Oxford University and AstraZeneca: interim guidance, 10 February 2021

Disability considerations during the COVID-19 outbreak, 2020

Ensuring continuity of cancer care while responding to the COVID-19 pandemic Experiences from Kyrgyzstan (2020) (produced by WHO/Europe)

Ensuring people-centred diabetes care during the COVID-19 pandemic Experiences from Portugal (2020) (produced by WHO/Europe)

Guidance on routine immunization services during COVID-19 pandemic in the WHO European Region, 20 March 2020 (produced by WHO/Europe)

Guiding principles for immunization activities during the COVID-19 pandemic: interim guidance, 26 March 2020

Maintaining a safe and adequate blood supply during the pandemic outbreak of coronavirus disease (‎‎‎‎COVID-19)‎‎‎‎: interim guidance, 20 March 2020

Mental health and psychosocial considerations during the COVID-19 outbreak, 18 March 2020

WHO Regional Office for Europe recommendations on influenza vaccination for the 2020/2021 season during the ongoing COVID-19 pandemic (2020)

Influenza vaccination is safe and the most effective means of preventing infection and severe outcomes caused by influenza viruses.
Health system considerations: when influenza meets COVID-19, revised version December 2020 (produced by WHO/Europe)

Interim recommendations for use of the Pfizer–BioNTech COVID-19 vaccine, BNT162b2, under emergency use listing: interim guidance, 8 January 2021

Operational guidance: COVID-19 vaccination data and information management, including monitoring of vaccine effectiveness, January 2021 (produced by WHO/Europe)

Operational guidance: acceptance and uptake of COVID-19 vaccines, January 2021 (produced by WHO/Europe)

Operational guidance: evidence-based decision-making process for developing national COVID-19 vaccination strategies, January 2021 (produced by WHO/Europe)

Operational guidance: management structure, advocacy and resources for COVID-19 vaccine deployment and vaccination, January 2021 (produced by WHO/Europe)

Strategic considerations in preparing for deployment of COVID-19 vaccine and vaccination in the WHO European Region, 9 October 2020 (produced by WHO/Europe)

This document outlines the key strategic considerations for ministries of health, their agencies, national immunization technical advisory groups/committees and relevant public and private sector authorities in the WHO European Region in preparing for deployment of COVID-19 vaccine and vaccination in their countries.
Operational considerations for influenza surveillance in the WHO European Region during COVID-19: interim guidance (2020) (produced by WHO/Europe)

Operational guidance: legal and regulatory framework facilitating vaccine deployment, January 2021 (produced by WHO/Europe)

Job aid for COVID-19 vaccine administration: Comirnaty® Pfizer/BioNTech BNT162b2 vaccine (‎international nonproprietary name: tozinameran)‎ (2021) (produced by WHO/Europe)

Fact sheet for health workers: Comirnaty® Pfizer/BioNTech BNT162b2 vaccine (‎international nonproprietary name: tozinameran)‎ (2021) (produced by WHO/Europe)

Job aid for COVID-19 vaccine administration: AZD1222 (ChAdOx1-S [recombinant]) COVID-19 vaccine* (International nonproprietary name: COVID-19 Vaccine (ChAdOx1-S [recombinant])) (2021) (produced by WHO/Europe)

Job aid for COVID-19 vaccine administration: Moderna COVID-19 (mRNA-1273) vaccine (2021)